Trial Profile
OPTIMA HCN2
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2009
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OPTIMA HCN2
- Sponsors Romark Laboratories
- 28 Feb 2009 New source identified and integrated (Romark media release). Interim results presented at 19th Conference of Asia Pacific Association for the Study of the Liver.
- 31 Dec 2007 New trial record.